Notice: This company has been marked as potentially delisted and may not be actively trading. Cerevel Therapeutics (CERE) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get the Latest News and Ratings for CERE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Cerevel Therapeutics and its competitors. Enter your email to sign up for newsletter Sign Up CERE Analyst Ratings Over TimeTypeCurrent Forecast11/15/23 to 11/14/241 Month Ago10/16/23 to 10/15/243 Months Ago8/17/23 to 8/16/241 Year Ago11/15/22 to 11/15/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy0 Buy rating(s)1 Buy rating(s)1 Buy rating(s)5 Buy rating(s)Hold7 Hold rating(s)7 Hold rating(s)7 Hold rating(s)4 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$45.00$44.13$44.13$32.78Forecasted Upside0.09% Upside-1.86% Downside-1.86% Downside35.61% UpsideConsensus RatingHoldHoldHoldModerate Buy Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover CERE Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History CERE Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Cerevel Therapeutics Stock vs. The CompetitionTypeCerevel TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 2.00 2.80 2.50Consensus RatingHoldModerate BuyModerate BuyPredicted Upside0.09% Upside25,253.10% Upside8.54% UpsideNews Sentiment RatingNeutral NewsSee Recent CERE NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails2/16/2024Mizuho2 of 5 stars Boost TargetNeutral ➝ Neutral$25.00 ➝ $45.00+5.71%12/28/2023JPMorgan Chase & Co.3 of 5 stars Boost TargetNeutral ➝ Neutral$25.00 ➝ $45.00+6.38%12/22/2023Jefferies Financial Group2 of 5 stars Reiterated RatingBuy ➝ Hold$40.00 ➝ $45.00+8.72%12/8/2023TD CowenSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOutperform ➝ Market Perform$45.00+9.41%12/7/2023HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingD. TsaoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$41.00 ➝ $45.00+9.78%12/7/2023Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingC. DuncanSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$38.00 ➝ $45.00+21.85% Get the Latest News and Ratings for CERE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/7/2023Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOverweight ➝ Neutral$33.00 ➝ $45.00+21.85%11/2/2023Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOverweight ➝ Overweight$42.00 ➝ $38.00+52.73%8/3/2023Bank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeBuy ➝ Neutral$36.00 ➝ $31.00+17.74%5/4/2023Wells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeEqual Weight ➝ Overweight$30.00-6.02%3/16/2023Berenberg BankSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageHold$22.00-10.02%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:35 PM ET. CERE Forecast - Frequently Asked Questions What is Cerevel Therapeutics' forecast for 2025? According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Cerevel Therapeutics is $45.00, with a high forecast of $45.00 and a low forecast of $45.00. Should I buy or sell Cerevel Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 7 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CERE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERE, but not buy additional shares or sell existing shares. Does Cerevel Therapeutics's stock price have much upside? According to analysts, Cerevel Therapeutics's stock has a predicted upside of 0.09% based on their 12-month stock forecasts. Do Wall Street analysts like Cerevel Therapeutics more than its competitors? Analysts like Cerevel Therapeutics less than other "medical" companies. The consensus rating for Cerevel Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CERE compares to other companies. Stock Forecasts and Research Tools Related Companies CNX Resources Stock Forecast Warrior Met Coal Stock Forecast Arch Resources Stock Forecast Hallador Energy Stock Forecast Teva Pharmaceutical Industries Stock Forecast BeiGene Stock Forecast United Therapeutics Stock Forecast Royalty Pharma Stock Forecast Genmab A/S Stock Forecast Summit Therapeutics Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Trump’s Back, but DC’s Coming for Your Money! (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov This page (NASDAQ:CERE) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerevel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CERE Stock Alerts